Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten Sells 23,671 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Dirk Kersten sold 23,671 shares of the company's stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now owns 99,652 shares of the company's stock, valued at approximately $3,522,698.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Dirk Kersten also recently made the following trade(s):

• On Wednesday, September 25th, Dirk Kersten sold 2,357 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.06, for a total transaction of $82,636.42.
• On Monday, September 23rd, Dirk Kersten sold 40,831 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.32, for a total transaction of $1,442,150.92.
• On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN traded up $0.51 during midday trading on Friday, reaching $35.24. 1,596,541 shares of the company's stock were exchanged, compared to its average volume of 1,540,210. The company's 50 day simple moving average is $37.55 and its two-hundred day simple moving average is $34.49. The firm has a market capitalization of $3.08 billion, a PE ratio of -8.88 and a beta of 1.05. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.02. On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

DYN has been the topic of several research reports. StockNews.com lowered shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, September 16th. Stifel Nicolaus raised their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Oppenheimer reiterated an "outperform" rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Piper Sandler reissued an "overweight" rating and issued a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. Finally, Morgan Stanley increased their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an "overweight" rating in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.40.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. RA Capital Management L.P. bought a new position in Dyne Therapeutics during the 1st quarter valued at about $140,666,000. Vanguard Group Inc. lifted its holdings in Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company's stock valued at $97,669,000 after purchasing an additional 1,110,629 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Dyne Therapeutics by 23,512.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company's stock valued at $75,915,000 after purchasing an additional 2,663,910 shares during the last quarter. Artal Group S.A. lifted its holdings in Dyne Therapeutics by 24.6% during the 1st quarter. Artal Group S.A. now owns 1,517,960 shares of the company's stock valued at $43,095,000 after purchasing an additional 300,000 shares during the last quarter. Finally, Federated Hermes Inc. lifted its holdings in Dyne Therapeutics by 10.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company's stock valued at $42,881,000 after purchasing an additional 114,888 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.